AILERON THERAPEUTICS INC (ALRN) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ALRN • US00887A2042

2.11 USD
+0.18 (+9.33%)
At close: Jan 10, 2025
2.11 USD
0 (0%)
After Hours: 1/10/2025, 8:00:59 PM
Fundamental Rating

2

Overall ALRN gets a fundamental rating of 2 out of 10. We evaluated ALRN against 524 industry peers in the Biotechnology industry. ALRN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALRN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • ALRN had negative earnings in the past year.
  • ALRN had a negative operating cash flow in the past year.
  • In the past 5 years ALRN always reported negative net income.
  • ALRN had a negative operating cash flow in each of the past 5 years.
ALRN Yearly Net Income VS EBIT VS OCF VS FCFALRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -28.06%, ALRN is in the better half of the industry, outperforming 70.55% of the companies in the same industry.
  • The Return On Equity of ALRN (-30.71%) is better than 78.31% of its industry peers.
Industry RankSector Rank
ROA -28.06%
ROE -30.71%
ROIC N/A
ROA(3y)-64.32%
ROA(5y)-86.69%
ROE(3y)-74.12%
ROE(5y)-115.87%
ROIC(3y)N/A
ROIC(5y)N/A
ALRN Yearly ROA, ROE, ROICALRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ALRN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALRN Yearly Profit, Operating, Gross MarginsALRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

  • The number of shares outstanding for ALRN has been increased compared to 1 year ago.
  • There is no outstanding debt for ALRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALRN Yearly Shares OutstandingALRN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
ALRN Yearly Total Debt VS Total AssetsALRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -1.90, we must say that ALRN is in the distress zone and has some risk of bankruptcy.
  • ALRN has a Altman-Z score of -1.90. This is comparable to the rest of the industry: ALRN outperforms 52.73% of its industry peers.
  • ALRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.9
ROIC/WACCN/A
WACCN/A
ALRN Yearly LT Debt VS Equity VS FCFALRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 3.30 indicates that ALRN has no problem at all paying its short term obligations.
  • With a Current ratio value of 3.30, ALRN is not doing good in the industry: 60.85% of the companies in the same industry are doing better.
  • ALRN has a Quick Ratio of 3.30. This indicates that ALRN is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of ALRN (3.30) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.3
Quick Ratio 3.3
ALRN Yearly Current Assets VS Current LiabilitesALRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

  • ALRN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.65%.
EPS 1Y (TTM)-9.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.52%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ALRN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.99% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.33%
EPS Next 2Y3.28%
EPS Next 3Y3.7%
EPS Next 5Y2.99%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALRN Yearly EPS VS EstimatesALRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • ALRN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALRN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALRN Price Earnings VS Forward Price EarningsALRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALRN Per share dataALRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.28%
EPS Next 3Y3.7%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for ALRN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AILERON THERAPEUTICS INC

NASDAQ:ALRN (1/10/2025, 8:00:59 PM)

After market: 2.11 0 (0%)

2.11

+0.18 (+9.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)N/A
Inst Owners31.86%
Inst Owner Change1.55%
Ins Owners0.65%
Ins Owner Change0%
Market Cap45.72M
Revenue(TTM)N/A
Net Income(TTM)-29.24M
Analysts85
Price Target13.26 (528.44%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.2%
Min EPS beat(2)-5.04%
Max EPS beat(2)35.44%
EPS beat(4)1
Avg EPS beat(4)-320.99%
Min EPS beat(4)-820.61%
Max EPS beat(4)35.44%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-118.18%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.16%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.48
P/tB 4.71
EV/EBITDA N/A
EPS(TTM)-3.12
EYN/A
EPS(NY)-1.92
Fwd EYN/A
FCF(TTM)-1.29
FCFYN/A
OCF(TTM)-1.29
OCFYN/A
SpS0
BVpS4.39
TBVpS0.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -28.06%
ROE -30.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.32%
ROA(5y)-86.69%
ROE(3y)-74.12%
ROE(5y)-115.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.3
Quick Ratio 3.3
Altman-Z -1.9
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.52%
EPS Next Y-11.33%
EPS Next 2Y3.28%
EPS Next 3Y3.7%
EPS Next 5Y2.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-132.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-4.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.33%
OCF growth 3YN/A
OCF growth 5YN/A

AILERON THERAPEUTICS INC / ALRN FAQ

Can you provide the ChartMill fundamental rating for AILERON THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to ALRN.


What is the valuation status of AILERON THERAPEUTICS INC (ALRN) stock?

ChartMill assigns a valuation rating of 0 / 10 to AILERON THERAPEUTICS INC (ALRN). This can be considered as Overvalued.


How profitable is AILERON THERAPEUTICS INC (ALRN) stock?

AILERON THERAPEUTICS INC (ALRN) has a profitability rating of 1 / 10.